Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience

This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety‐five patients with R/R HL, who received BV in 20 centers from Greece, were an...

Descripción completa

Detalles Bibliográficos
Autores principales: Angelopoulou, Maria K., Vassilakopoulos, Theodoros P., Batsis, Ioannis, Sakellari, Ioanna, Gkirkas, Konstantinos, Pappa, Vasiliki, Giannoulia, Panagiota, Apostolidis, Ioannis, Apostolopoulos, Christos, Roussou, Paraskevi, Panayiotidis, Panayiotis, Dimou, Maria, Kyrtsonis, Marie‐Christine, Palassopoulou, Maria, Vassilopoulos, Georgios, Moschogiannis, Maria, Kalpadakis, Christina, Margaritis, Dimitrios, Spyridonidis, Alexander, Michalis, Eurydiki, Anargyrou, Konstantinos, Repousis, Panagiotis, Hatzimichael, Eleutheria, Bousiou, Zoi, Poulakidas, Elias, Grentzelias, Dimitrios, Harhalakis, Nikolaos, Pangalis, Gerassimos A., Anagnostopoulos, Achilles, Tsirigotis, Panagiotis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836920/
https://www.ncbi.nlm.nih.gov/pubmed/28219112
http://dx.doi.org/10.1002/hon.2383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836920/
https://www.ncbi.nlm.nih.gov/pubmed/28219112
http://dx.doi.org/10.1002/hon.2383

Ejemplares similares